 CLEVELAND, July 7, 2021 PRNewswire -- ViewRay, Inc. NASDAQ: VRAY today announced that the Miami Cancer Institute, part of Baptist Health South Florida, has enrolled the first patients in its Stereotactic MRI-guided Adaptive Radiation Therapy SMART in One Fraction for Inoperable Primary or Metastatic Carcinoma clinical study referred to as the SMART ONE trial NCT04939246. This single-arm prospective study that was developed and led by Dr. Michael Chuong, MD, FACRO, radiation oncologist and Medical Director of Proton Therapy and MR-guided Therapy at Miami Cancer Institute, is exploring the feasibility and tolerability of single-fraction stereotactic ablative body radiation therapy SABR for primary or metastatic carcinoma involving the lung, liver, adrenal gland, abdominalpelvic lymph node, pancreas, and kidney. 